Intuitive Surgical Stock Falls Despite da Vinci 5 Placements Jum
Intuitive Surgical ISRG reported Q3 non-GAAP EPS of $3.00, beating estimates, on revenue of $3.05B, also above forecasts. GAAP EPS fell due to a $450M litigation charge. Shares dropped 7.76% premarket. Revenue rose 22%, driven by procedure growth and higher lease revenue. The company placed 546 da Vinci systems, up from 427 a year earlier. For 2026, Intuitive expects da Vinci procedure growth of 14-15% and non-GAAP gross margin of 68.7-69.3%.
How this was made
The 30-second read
Why it matters
The earnings beat is offset by the settlement charge, leading to a pre‑market decline; investors may reassess risk exposure.
Market read
Earnings release with material numbers and a large buyback creates immediate trading opportunity.
What to watch
Strong procedure growth and margin expansion could offset settlement concerns.
Background
Intuitive Surgical's Q3 results include a non‑GAAP EPS beat, a $450M antitrust settlement, and a $2.94B share repurchase.
Ticker impact
Intuitive Surgical reported Q3 non‑GAAP EPS beat, disclosed a $2.94B share buyback and guidance, and its shares fell 7.76% pre‑market.
likely further downside as investors digest the settlement charge and modest guidance
The stock dropped 7.76% pre‑market on the same day of the earnings release, indicating immediate sell pressure.
Market effects
Robotic surgery equipment sector may see heightened scrutiny on litigation risks.
U.S. healthcare equipment stocks could experience short‑term volatility.
Limited to investors in medical‑device equities.
Counterpoint
Buyback size may support longer‑term valuation despite short‑term sell‑off.
Key entities
- CompanyIntuitive Surgical
Medical‑device maker of da Vinci surgical systems.
